Clinical Overview
Zonisamide is an anticonvulsant indicated for adjunctive therapy in partial seizures. It has a unique mechanism involving multiple targets including sodium and calcium channels, and has shown off-label efficacy for bipolar disorder, migraine prevention, and weight loss. It is a sulfonamide derivative requiring monitoring for hypersensitivity reactions.
Primary Clinical Applications
Zonisamide is indicated as adjunctive therapy for partial seizures in adults and children over 16 years. It has extensive off-label use for bipolar disorder (particularly mixed states and rapid cycling), migraine prevention, and binge eating disorder due to its mood-stabilizing properties and appetite suppressant effects.
Mechanism and Clinical Benefits
Zonisamide blocks voltage-sensitive sodium and T-type calcium channels, modulates GABA and glutamate neurotransmission, and inhibits carbonic anhydrase. This multi-target mechanism provides broad-spectrum anticonvulsant activity and may contribute to its mood-stabilizing and weight-reducing effects.
Clinical Considerations
Zonisamide has a very long half-life (63 hours) allowing for once-daily dosing but requiring patience for steady-state effects and careful monitoring during dose changes. It commonly causes weight loss and cognitive effects, particularly at higher doses. As a sulfonamide, it requires monitoring for serious hypersensitivity reactions including Stevens-Johnson syndrome.
Prescribing Information
Dosing & Administration
Partial Seizures – Adults and Children >16 years:
- Initial: 100 mg once daily
- Titration: May increase by 100 mg daily every 2 weeks
- Range: 200-600 mg daily
- Maximum: 600 mg daily
Off-label Bipolar Disorder:
- Initial: 100 mg once daily
- Range: 100-600 mg daily
- Titrate slowly based on response and tolerance
Administration:
- Take once daily with or without food
- Swallow capsules whole, do not open or chew
- Consistent timing each day
- Maintain adequate hydration
Indications
- Adjunctive therapy for partial seizures in adults and children ≥16 years
- Off-label: Bipolar disorder, migraine prevention, weight management
Contraindications
- Hypersensitivity to zonisamide or sulfonamides
- No absolute contraindications
Warnings & Precautions
- Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis
- Suicidal thoughts: Monitor for behavioral changes
- Metabolic acidosis: Monitor serum bicarbonate
- Kidney stones: Maintain adequate hydration
- Oligohidrosis and hyperthermia: Particularly in pediatric patients
- Cognitive effects: Somnolence, confusion, difficulty concentrating
Drug Interactions
- CYP3A4 inducers: May decrease zonisamide levels
- Carbonic anhydrase inhibitors: Increased risk of kidney stones
- CNS depressants: Enhanced sedation
Adverse Reactions
Common (≥10%):
- Somnolence, dizziness, anorexia, headache
- Nausea, agitation/irritability
Weight loss:
- Significant weight loss common (average 3-9 kg)
Serious:
- Stevens-Johnson syndrome, kidney stones, metabolic acidosis
Special Populations
- Renal Impairment: Use caution, slower titration may be needed
- Hepatic Impairment: Use caution, may require dose reduction
- Pregnancy: Category C – use only if benefits outweigh risks
- Hydration: Maintain adequate fluid intake to prevent kidney stones
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
